Table S2.
Agreement between MoBa and NorPD for 4-week intervals in MoBa Q1 and MoBa Q3
| THRT | MoBa totala | NorPD totala | MoBa only | NorPD only | Both | Neither | Agreement | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | n | n | n | κb (95% CI) | Rangec | ||
| Q1 | Weeks 0–4 | 959 | 1.7 | 923 | 1.6 | 231 | 202 | 721 | 54,987 | 0.76 (0.76–0.77) | S |
| Weeks 5–8 | 968 | 1.7 | 941 | 1.7 | 238 | 211 | 730 | 54,969 | 0.76 (0.75–0.77) | S | |
| Weeks 9–12 | 978 | 1.7 | 960 | 1.7 | 232 | 214 | 746 | 54,956 | 0.77 (0.76–0.77) | S | |
| Q3 | Weeks 13–16d | 1,065 | 1.9 | 957 | 1.7 | 262 | 154 | 803 | 54,929 | 0.79 (0.78–0.80) | S |
| Weeks 17–20 | 330 | 0.6 | 985 | 1.7 | 68 | 723 | 262 | 55,095 | 0.39 (0.38–0.40) | f | |
| Weeks 21–24 | 334 | 0.6 | 1,031 | 1.8 | 69 | 766 | 265 | 55,048 | 0.38 (0.37–0.39) | f | |
| Weeks 25–28 | 338 | 0.6 | 1,042 | 1.8 | 66 | 770 | 272 | 55,040 | 0.39 (0.38–0.40) | f | |
Notes:
a
Total study population, n=56,148.
b
Cohen’s kappa coefficient (k).
c
Subdivision of agreement by Landis and Koch: <0, no (no); 0–0.20, slight (s); 0.21–0.40, fair (f); 0.41–0.60, moderate (m); 0.61–0.80, substantial (S); and 0.81–1.00, perfect (P).
d
Weeks 13–16 aggregate the text box “week 13+” from MoBa Q1 and “weeks 13–16” from MoBa Q3.
Abbreviations: MoBa, Norwegian Mother and Child Cohort Study; MoBa Q1, MoBa questionnaire 1; MoBa Q3, MoBa questionnaire 3; NorPD, Norwegian Prescription Database; THRT, thyroid hormone replacement therapy.